Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity

Ian R. Munhenzva, Connor W. Barth, Martha Sibrian-Vazquez, Lei G. Wang, Jorge O. Escobedo, Summer Gibbs, Robert M. Strongin

Research output: Contribution to journalArticle

Abstract

The current five-year survival rate of <5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.

Original languageEnglish (US)
JournalMethods
DOIs
StatePublished - Jan 1 2019

Fingerprint

Fluorophores
Pancreatic Neoplasms
Adenocarcinoma
Tissue
Ducts
Coloring Agents
Fluorescence
Imaging techniques
Staining and Labeling
Delayed Diagnosis
Frozen Sections
ROC Curve
Pancreas

Keywords

  • Benzoxanthene
  • Fluorescence imaging
  • Frozen section
  • Pancreatic cancer
  • PanIN
  • PDAC
  • Tumor targeting

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity. / Munhenzva, Ian R.; Barth, Connor W.; Sibrian-Vazquez, Martha; Wang, Lei G.; Escobedo, Jorge O.; Gibbs, Summer; Strongin, Robert M.

In: Methods, 01.01.2019.

Research output: Contribution to journalArticle

Munhenzva, Ian R. ; Barth, Connor W. ; Sibrian-Vazquez, Martha ; Wang, Lei G. ; Escobedo, Jorge O. ; Gibbs, Summer ; Strongin, Robert M. / Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity. In: Methods. 2019.
@article{f84c99183ccf4e618d2ab9173171f925,
title = "Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity",
abstract = "The current five-year survival rate of <5{\%} for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.",
keywords = "Benzoxanthene, Fluorescence imaging, Frozen section, Pancreatic cancer, PanIN, PDAC, Tumor targeting",
author = "Munhenzva, {Ian R.} and Barth, {Connor W.} and Martha Sibrian-Vazquez and Wang, {Lei G.} and Escobedo, {Jorge O.} and Summer Gibbs and Strongin, {Robert M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ymeth.2019.06.008",
language = "English (US)",
journal = "Methods in Enzymology",
issn = "1046-2023",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity

AU - Munhenzva, Ian R.

AU - Barth, Connor W.

AU - Sibrian-Vazquez, Martha

AU - Wang, Lei G.

AU - Escobedo, Jorge O.

AU - Gibbs, Summer

AU - Strongin, Robert M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The current five-year survival rate of <5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.

AB - The current five-year survival rate of <5% for pancreatic ductal adenocarcinoma (PDAC) is compounded by late diagnosis, a lack of PDAC-specific intraoperative guidance to ensure complete resection, and the ineffectiveness of current therapies. Previously, utilizing compound 1, a fluorophore with inherent PDAC selectivity, PDAC was visualized both in vivo and ex vivo in a murine model. In the current study, human PDAC tissue is targeted. Compound 1 selectively stains ducts of the adenocarcinoma versus the surrounding stroma, enabling the imaging of PDAC in frozen tissue sections with high contrast. To enhance the potential of 1 for intraoperative applications, the ex vivo staining protocol was optimized for rapid margin assessment, with a final staining time of ~15 min. To measure diagnostic performance, the area under a receiver operating characteristic (ROC) curve was measured for the identification of ductal adenocarcinoma vs. stroma. The bright fluorescence contrast enabled quantitative determination of PDAC (or precancerous PanIN lesions) versus healthy pancreas tissue in human tissue array samples.

KW - Benzoxanthene

KW - Fluorescence imaging

KW - Frozen section

KW - Pancreatic cancer

KW - PanIN

KW - PDAC

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=85067230885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067230885&partnerID=8YFLogxK

U2 - 10.1016/j.ymeth.2019.06.008

DO - 10.1016/j.ymeth.2019.06.008

M3 - Article

JO - Methods in Enzymology

JF - Methods in Enzymology

SN - 1046-2023

ER -